Method for determining the methicillin resistance of staphylococcus aureus strains

EP4463561A1Pending Publication Date: 2024-11-20UNIV CLAUDE BERNARD LYON 1 +5
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023703516
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-13
Filing Date
2023-01-11
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

Current methods for detecting methicillin-resistant Staphylococcus aureus (MRSA) strains are either time-consuming, costly, or require subculture steps, limiting their effectiveness in clinical settings where rapid and accurate identification is crucial for appropriate antibiotic treatment.

Method used

A method involving incubation of a biological sample in the presence of cefoxitin or 6-aminopenicillanic acid to induce PBP2a or PBP2c protein expression, followed by bacterial lysis and targeted mass spectrometry for peptide analysis, allowing direct detection from blood cultures without subculture, within less than 1.5 hours.

Benefits of technology

This approach achieves sensitivity and specificity close to 100% for detecting MRSA strains, including variants, with rapid sample preparation and low costs, making it suitable for systematic use in clinical laboratories.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

The present invention relates to a method for determining the methicillin-resistance properties of a Staphylococcus aureus strain present in a biological sample, the method comprising the following steps: • a) incubating the biological sample containing the Staphylococcus aureus strain for at least 15 minutes in the presence of an antibiotic from the class of beta-lactams selected from the following group: cefoxitin and 6-APA (6-aminopenicillanic acid); • b) isolating the bacteria present in the biological sample; • c) lysing the bacteria and hydrolysing the bacterial proteins in order to obtain a mixture of peptides; and • d) analysing this mixture of peptides by targeted mass spectrometry, the detection of at least one peptide originating from the protein PBP2a (SEQ ID NO. 1) or PBP2c (SEQ ID NO. 2) during this analysis step being indicative of the methicillin resistance of the Staphylococcus aureus strain present in the biological sample.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] METHOD FOR DETERMINING THE RESISTANCE TO METICILLIN OF STAPHYLOCOCCUS AUREUS STRAIN

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to a method for characterizing bacterial strains belonging to the staphylococcus family, and in particular to a method for identifying bacterial strains resistant to certain antibiotics. This allows healthcare personnel to select antibiotics suitable for each infected patient, based on these resistance data.

[0004] STATE OF THE ART

[0005] The increased use of antibiotics in recent decades has led to the emergence of resistance mechanisms in many bacterial species.

[0006] The first penicillin-resistant strains of Staphylococcus aureus (golden staphylococci) were characterized only two years after the introduction of this antibiotic into the treatment chain for bacterial infections (Kirby, 1944) and spread rapidly, leading to the gradual cessation of the use of penicillin in the clinic in favor of new semi-synthetic antibacterial molecules such as methicillin and oxacillin.

[0007] Then, in the 1960s, new strains of Staphylococcus aureus emerged that were resistant to methicillin, but also to other antibiotic compounds. These strains are referred to by the acronym MRSA or, more commonly, by their English acronym MRSA (Methicillin-Resistant Staphylococcus ureus).

[0008] These MRSA strains express a specific toxin, LPV or Panton-Valentine leukocidin. This so-called "pore-forming" toxin induces pores in cell walls, particularly those of the immune system, thus killing cells capable of fighting the infection.

[0009] Although initially confined to hospitals, MRSA strains have since spread throughout the population. In 2019, MRSA strains were estimated to account for between 1% and 46% of Staphylococcus aureus infections in Europe. According to the World Health Organization, a person infected with an MRSA strain has a 64% higher probability of death than a person infected with a non-resistant strain.

[0010] The detection of MRSA strains is therefore a major challenge for the management and treatment of patients with Staphylococcus aureus infections. The MRSA phenotype is due to the expression of a specific protein, PBP2a for "Penicillin binding protein 2a", encoded by the Mec A gene, and in rarer cases to the expression of the PBP2c protein encoded by the ecC gene. These proteins "replace" the transpeptidase PBP2, an enzyme involved in the formation of the bacterial cell wall. Since the alternative proteins PBP2a and PBP2c have a low affinity for methicillin and penicillin, the presence of these antibiotics does not inhibit their activity, and cell wall synthesis continues normally, thus ensuring bacterial growth even in the presence of these antibiotics.

[0011] Since the appearance of the first MRSÀ strains, several methods for detecting this resistance property have been developed, using three main approaches:

[0012] - Phenotypic methods are based on an assessment of bacterial growth in the presence of antibiotics;

[0013] - Molecular biology methods are based on the detection of MecÀ and / or MecC genes in the bacterial genome of the strains studied;

[0014] - Immunological and proteomic methods are based on the detection of the PBP2a protein or its peptides. Among these technologies, immunochromatography (detection using antibodies) and mass spectrometry methods are particularly used.

[0015] These different approaches are briefly presented below.

[0016] Phenotypic methods

[0017] Traditional agar diffusion methods, although old, are still widely used in laboratories due to their simplicity and low cost. They consist of growing the bacteria on agar in the presence of an antibiotic disc, usually oxacillin or cefoxitin. The sensitive or resistant phenotype of the bacterial strain is determined by evaluating the diameter of the growth inhibition zone around the disc.

[0018] The main disadvantage of this technology is the time required, approximately 12 to 18 hours, to obtain the result (Felten, 2002).

[0019] The arrival on the market of instruments such as the Vitek® 2 distributed by BioMérieux, or the Phoenix™ distributed by Becton Dickinson, has enabled high-throughput automation of antibiotic susceptibility testing. Although more robust than agar diffusion methods, these tests are also limited by the growth time of the bacteria. The result is, in the case of Staphylococcus aureus, obtained in approximately 10 to 13 hours.

[0020] For example, the article by Sparbier et al., 2013, discloses such a phenotypic method where bacterial growth is assessed in the presence of antibiotics. Bacteria are incubated in the presence of oxacillin or cefoxitin, and “charged” lysine with a high molecular weight. Incorporation of this charged amino acid will only be observed in newly synthesized proteins. However, only antibiotic-resistant bacteria exhibit significant protein biosynthesis activity. Proteins comprising charged lysine are then detected by MÀLDI-TOF.

[0021] The major drawback of this so-called "phenotypic" technology is that it is sensitive to factors that can influence bacterial growth, such as the volume of inoculum, the duration and temperature of incubation, the medium, the pH or even the salt concentration (Tenover et al., 1999).

[0022] Molecular biology methods

[0023] The advent of molecular biology methods has significantly improved the identification times for MRSΔ strains compared to phenotypic methods. The high sensitivity and specificity of currently marketed tests make detection of the MecA gene by PCR (Polymerase Chain Reaction) the "gold standard" for MRSΔ diagnosis. Commonly used tests include geneXpert MRSΔ / SΔ BC distributed by Cepheid, GeneOhm™ StaphSR Assay distributed by Becton Dickinson, eazyplexOMRSAplus distributed by AmplexDiagnostics, and FilmArray BCID distributed by Biomérieux. These tests allow the detection of MRSA strains in 1 to 3 hours, directly from a positive blood culture bottle, eliminating the need for prior subculture steps, which involve isolating and proliferating the bacteria.

[0024] The main disadvantage of this technology is that it tends to generate "false positives", particularly in the case of strains carrying an SSCmec cassette not containing the MecA gene, or for strains expressing a variant protein encoded by a gene with a sequence slightly different from that established for the MecA gene.

[0025] Moreover, the high cost of molecular biology analysis remains a major obstacle to their systematic use.

[0026] Immunological tests: detection of the PBP2A protein

[0027] The use of latex beads coupled with a specific monoclonal antibody detecting the PBP2a protein allows visualization of agglutination with the naked eye, indicating the presence of the antigen in the sample. This is the principle on which the PBP2' Oxoid tests distributed by Thermofischer Scientific or Mastalex-MRSA distributed by Mast Diagnostic are based.

[0028] The test itself takes between 15 and 20 minutes. This test has very good performance with a sensitivity of 100% and a specificity greater than 99%. The major disadvantage of this technique is that it requires a minimum quantity of 1.5 x 10 9 bacteria in the tested sample, which involves a bacterial culture step lasting at least 10 hours.

[0029] Furthermore, these tests do not allow the detection of MRSα strains expressing the PBP2c protein, which is not recognized by some monoclonal antibodies used. This has been shown in particular for the PBP2' Oxoid test (Dupieux et al., 2017).

[0030] Immunochromatographic tests have also been marketed for the detection of MRSÀ strains, for example the Clearview™ PBP2a SÀ Culture Colony Test kit distributed by Àlere.

[0031] Although very rapid and having a sensitivity and specificity greater than 98%, this test also requires a bacterial culture step.

[0032] The Clearview™ PBP2a SÀ Culture Colony Test can advantageously detect PBP2c from colonies growing at the edge of a cefoxitin disc after culture on agar. This induction step, necessary for the detection of MecC, however, results in an additional delay of approximately 18 hours before the results are returned (Dupieux et al., 2017).

[0033] Targeted mass spectrometry

[0034] Recent studies have highlighted the potential of so-called "bottom-up" proteomic approaches, i.e. based on peptide fragmentation spectra by targeted mass spectrometry, for the identification of pathogens and the demonstration of resistance mechanisms.

[0035] These approaches include the following steps:

[0036] 1) A lysis, mechanical or chemical, of the bacterial sample in order to release the intracellular proteins,

[0037] 2) Enzymatic digestion of bacterial proteins using proteases (typically trypsin) to generate a mixture of peptides

[0038] 3) A chromatographic separation coupled with a targeted mass spectrometry analysis of the sample, where the mass spectrometer operates in MS / MS mode for the detection of marker peptides of resistance proteins

[0039] 4) Reprocessing of results for validation of the presence / absence of marker peptides in the sample.

[0040] The term "targeted" indicates that specific peptide sequences are sought; these can be whole protein sequences or peptides resulting from enzymatic digestion of said proteins. Targeted mass spectrometry has been successfully used to characterize the resistance and virulence of Staphylococcus aureus strains by detecting, in particular, the PBP2a protein or virulence factors such as PVL (Charretier et al., 2015).

[0041] International application WO 2011 / 045544 describes a method comprising the characterization of the resistance and virulence of Staphylococcus aureus by liquid chromatography coupled with targeted mass spectrometry, where the starting biological material is a colony isolated on agar medium.

[0042] Finally, it has recently been shown that the PBP2a protein can be detected in its intact form, after separation by liquid chromatography and MS analysis (“top-down” technology based on the analysis of whole protein fragmentation spectra). In the absence of the enzymatic digestion step of the protein, the time required to obtain a result is shortened (Neil et al., 2021). However, the authors did not demonstrate the applicability of their method to the detection of PBP2a directly in blood culture samples, without a prior subculture step.

[0043] To date, no technology is known that meets all the criteria required for implementation in a hospital environment, including short analysis time, simplicity of sample preparation, limited cost and satisfactory performance.

[0044] To meet the current needs of analytical laboratories, a method for identifying MRSA strains should meet at least the following criteria:

[0045] - No subculture step of bacteria isolated from the blood (analysis directly from the blood culture bottle when it is detected as positive),

[0046] - short sample preparation and analysis time (less than 2 hours) in order to obtain a result quickly, and thus allow the administration of appropriate antibiotic treatment to the patient as quickly as possible,

[0047] - low cost so that the test can be carried out systematically,

[0048] - test detecting both PBP2a and PBP2c proteins with a sensitivity and specificity close to 100%, including variant proteins having a peptide sequence showing sequence identity with the sequences SEQ ID NO. 1 or 2.

[0049] The inventors have developed a targeted method for detecting MRSA strains by liquid chromatography coupled with mass spectrometry, carried out directly from a positive blood culture bottle, including an induction step and rapid sample preparation, and making it possible to obtain a result in less than 1.5 hours from the detection of the presence of a strain of Staphylococcus aureus in a biological sample.

[0050] STATEMENT OF THE INVENTION The present invention relates to a method for determining the methicillin resistance properties of a strain of Staphylococcus aureus present in a biological sample, comprising the following steps: a) incubation of the biological sample containing said strain of S. aureus for at least 15 minutes, in the presence of an antibiotic of the beta-lactam class chosen from the following group: cefoxitin and 6-ΔPA (6-aminopenicillanic acid), b) isolation of the bacteria present in said biological sample, c) lysis of the bacteria and hydrolysis of the bacterial proteins, in order to obtain a mixture of peptides, d) analysis of this mixture of peptides by targeted mass spectrometry, the detection of at least one peptide derived from the protein PBP2a (SEQ ID NO. 1) or PBP2c (SEQ ID NO.2) during this analysis step being indicative of the resistance to methicillin of the strain of Staphylococcus aureus present in said biological sample.

[0051] The present invention also relates to a kit for implementing this method, comprising:

[0052] - an antibiotic of the beta-lactam class chosen from the following group: cefoxitin and 6-ÀPÀ (6-aminopenicillanic acid),

[0053] - trypsin,

[0054] - a reagent allowing selective lysis of non-bacterial cells present in the biological sample, in particular a detergent chosen from saponin, Triton X100 and Sodium Dodecyl Sulfate (SDS),

[0055] - optionally, reagents for carrying out targeted mass spectrometry.

[0056] DESCRIPTION OF FIGURES

[0057] Figure 1 represents a chromatogram resulting from an MRM-type analysis of the MRSA26b strain. A) Sample prepared without the induction step. B) Sample prepared with the induction step. Peaks corresponding to the transitions of the PBP2a peptides are indicated by arrows.

[0058] Figure 2 shows the chromatograms resulting from an MRM3-type analysis of the MRSA26b strain. A1 and A2) MRM3 chromatograms of the peptides VALELGSK (A1) and FQITTSPGSTQKK (A2) for the sample prepared without the induction step. B1 and B2) MRM3 chromatograms of the peptides VALELGSK (B1) and FQITTSPGSTQKK (B2) for the sample prepared with the induction step.

[0059] Figure 3 represents a chromatogram resulting from an MRM-type analysis of the MRSA28b strain. A) Sample prepared without the induction step. B) Sample prepared with the induction step. The peaks corresponding to the transitions of the PBP2a peptides are indicated by arrows. Figure 4 represents the chromatograms resulting from an MRM3-type analysis of the MRSA28b strain. A1 and A2) MRM3 chromatograms of the peptides VÀLELGSK (A1 ) and FQITTSPGSTQKK (A2) for the sample prepared without the induction step. B1 and B2) MRM3 chromatograms of the peptides VÀLELGSK (B1 ) and FQITTSPGSTQKK (B2) for the sample prepared with the induction step.

[0060] Figure 5 shows chromatograms of strain MSSÀ16b after an induction step. A) MRM chromatograms. B1 and B2) MRM3 chromatograms for peptides VÀLELGSK (B1) and FQITTSPGSTQKK (B2). No peptides are detected for both types of analysis.

[0061] Figure 6 shows chromatograms of strain MSSAI b after an induction step. A) MRM chromatograms. B1 and B2) MRM3 chromatograms for the peptides VALELGSK (B1) and FQITTSPGSTQkk (B2). No peptides are detected for both types of analysis.

[0062] Figure 7 represents a chromatogram resulting from an MRM-type analysis of a strain expressing PBP2c. A) Sample prepared without the induction step. B) Sample prepared with the induction step. Peaks corresponding to PBP2c peptide transitions are indicated by arrows.

[0063] DETAILED DESCRIPTION OF THE INVENTION

[0064] The present invention relates to a method for detecting strains of Staphylococcus aureus resistant to methicillin, known as MRAS strains, making it possible to obtain a result in less than 1.5 hours from a biological sample identified as containing a strain of S. aureus.

[0065] Methicillin, also spelled methicillin, is a beta-lactam antibiotic belonging to the penicillin subfamily. Its CAS number is 61-32-5. It was widely used against Staphylococcus aureus infections before being supplanted by cloxacillin, which poses less risk of bacterial resistance.

[0066] Advantageously, the method of the invention makes it possible to identify strains resistant to this antibiotic (MRAS) with a sensitivity and specificity close to 100%.

[0067] The method according to the invention uses a biological sample without a bacterial subculture step, for example a positive blood culture sample (containing blood cells and bacteria). A first step of inducing expression of the PBP2a or PBP2c protein, using an antibiotic of the beta-lactam class, is followed by a step of rapid isolation of the bacteria, then a step of lysis of the bacteria and enzymatic digestion of the proteins, and finally an analysis by targeted mass spectrometry for the detection of peptides resulting from the enzymatic digestion of the PBP2a or PBP2c protein.

[0068] Thus, the present invention relates to a method for determining the methicillin resistance properties of a strain of Staphylococcus aureus present in a biological sample, comprising the following steps: a) incubation of the biological sample containing said strain of Staphylococcus aureus for at least 15 minutes, in the presence of an antibiotic of the beta-lactam class chosen from the following group: cefoxitin and 6-APA (6-aminopenicillanic acid), b) isolation of the bacteria present in said biological sample, c) lysis of the bacteria and hydrolysis of the bacterial proteins, in order to obtain a mixture of peptides, d) analysis of this mixture of peptides by targeted mass spectrometry, the detection of at least one peptide from the PBP2a or PBP2c protein during this analysis step being indicative of the methicillin resistance of the strain of Staphylococcus aureus present in said biological sample.

[0069] This method was developed from the method described in international application WO 2011 / 045544.

[0070] Based on this method, the inventors identified that the PBP2a protein is expressed very heterogeneously among MRSA strains, at very different expression levels.

[0071] Using a methodology similar to that presented in application WO 2011 / 045544, but with a blood culture medium positive for Staphylococcus aureus as the starting biological sample, i.e. without a bacterial subculture step, it was demonstrated on a cohort of 98 MRSA strains representative of French epidemiology that approximately 60% of said MRSA strains present a level of expression of PBP2a too low to be able to be detected by the methodology described (see experimental section).

[0072] Indeed, heterogeneity in PBP2a expression exists between different MRSA strains. Some strains naturally express PBP2a at high levels (detectable without induction) and others have very low basal expression levels, not allowing the detection of PBP2a by direct analysis, without an induction step.

[0073] It was therefore concluded that the technology described in application WO 2011 / 045544 is not suitable for implementation in a clinical analysis laboratory, since many MRSA strains cannot be detected.

[0074] The present application relates to an improvement of said method, consisting of the addition of a step (a) of incubation of the biological sample containing said strain of S. aureus for at least 15 minutes, in the presence of a beta-lactam antibiotic, to induce the expression of the PBP2a protein or the PBP2c protein and thus have a new expression sufficient to detect the variant protein expressed in 100% of the MRSÀ strains.

[0075] The PBP2a protein has the following sequence:

[0076] Sequence 1, PBP2a, Staphylococcus aureus (NCBI ID: WP_001801873.1):

[0077] <h2 style=";text-align:left;direction:ltr">MMKKIKIVPLILIWWGFGIYFYASKDKEINNTIDAIEDKNFKQVYKDSSYISKSDNGEVEMTERPIKIYNSLGV KDINIQDRKIKKVSKNKKRVDAQYKIKTNYGNIDRNVQFNFVKEDGMWKLDWDHSVIIPGMQKDQSIHIENL KSERGKILDRNNVELANTGTAYEIGIVPKNVSKKDYKAIAKELSISEDYIKQQMDQNWVQDDTFVPLKTVKKM DEYLSDFAKKFHLTTNETESRNYPLGKATSHLLGYVGPINSEELKQKEYKGYKDDAVIGKKGLEKLYDKKLQ HEDGYRVTIVDDNSNTIAHTLIEKKKKDGKDIQLTIDAKVQKSIYNNMKNDYGSGTAIHPQTGELLALVSTPS YDVYPFMYGMSNEEYNKLTEDKKEPLLNKFQITTSPGSTQKILTAMIGLNNKTLDDKTSYKIDGKGWQKDKS WGGYNVTRYEWNGNIDLKQAIESSDNIFFARVALELGSKFEKGMKKLGVGEDIPSDYPFYNAQISNKNLD NEILLADSGYGQGEILINPVQILSIYSALENNGNINAPHLLKDTKNKVWKKNIISKENINLLTDGMQQWNKTH KEDIYRSYANLIGKSGTAELKMKQGETGRQIGWFISYDKDNPNMMMAINVKDVQDKGMASYNAKISGKVYD ELYENGNKKYDIDE<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0078] <h2 style=";text-align:left;direction:ltr"> The protein PBP2c has been present in the following sequence:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0079] <h2 style=";text-align:left;direction:ltr"> Sequence 2, PBP2c, Staphylococcus aureus (NCBI ID: WP_000725529.1 ):<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0080] MKKIYISVLVLLLIMIIITWLFKDDDIEKTISSIEKGNYNEVYKNSSEKSKLAYGEEEIVDRNKKIYKDLSVNNLKIT NHEIKKTGKDKKQVDVKYNIYTKYGTIRRNTQLNFIYEDKHWKLDWRPDVIPVPGLKNGQKINIETLKSERGKI KDRNGIELAKTGNTYEIGIVPNKTPKEKYDDIARDLQIDTKAITNKVNQKWVQPDSFVPIKKINKQDEYIDKLI KSYNLQINTIKSRVYPLNEATVHLLGYVGPINSDELKSKQFRNYSKNTVIGKKGLERLYDKQLQNTDGFKVSI ANTYDNKPLDTLLEKKAENGKDLHLTIDARVQESIYKHMKNDDGSGTALQPKTGEILALVSTPSYDVYPFMN GLSNNDYRKLTNNKKEPLLNKFQITTSPGSTQKILTSIIALKENKLDKNTNFDIYGKGWQKDASWGNYNITRF KWDGNIDLKQAIESSDNIFFARIALALGAKKFEQGMQDLGIGENIPSDYPFYKAQISNSNLKNEILLADSGYG DIDQ

[0081] Advantageously, the method of the present invention makes it possible to detect both PBP2a and PBP2c proteins, but also variant proteins.

[0082] The term "variant protein" means a protein having a peptide sequence having a high sequence identity with the sequences SEQ ID NO. 1 or 2, in particular a sequence identity of at least 90%, or better still at least 95%, or even 99% with one of the sequences SEQ ID NO. 1 or SEQ ID NO. 2. Variant proteins generally have one, two or three point mutations in the sequences of the wild-type proteins, i.e. they differ only for one, two or three amino acids in the peptide sequence. The percentages of identity referred to in the context of the disclosure of the present invention are determined after optimal alignment of the sequences to be compared, which may therefore comprise one or more additions, deletions, truncations and / or substitutions.

[0083] This percentage of identity can be calculated by any sequence analysis method well known to those skilled in the art.

[0084] The percentage of identity can be determined after global alignment of the sequences to be compared taken in their entirety, over their entire length. In addition to manually, it is possible to determine the global alignment of sequences using the algorithm of Needleman and Wunsch (1970).

[0085] For amino acid sequences, the sequence comparison can be performed using any software well known to those skilled in the art, such as Needle software. The parameters used may include, in particular: “Gap Open” equal to 10.0, “Gap Extend” equal to 0.5 and the BLOSUM62 matrix.

[0086] Preferably, the percentage of identity defined within the framework of the present invention is determined by means of a global alignment of the sequences to be compared over their entire length.

[0087] Step (a) of induction of PBP2a or PBP2c expression

[0088] Induction consists of carrying out a rapid incubation (in particular, for less than 3 hours and preferably less than one hour) in the presence of an antibiotic in order to activate the systems regulating the expression of PBP2a or PBP2c proteins and thus lead to overexpression of these proteins.

[0089] This incubation of the biological sample containing said strain of Staphylococcus aureus for at least 15 minutes, in the presence of an antibiotic of the beta-lactam class chosen from cefoxitin and 6-ÀPÀ (6-aminopenicillanic acid), induces the expression of at least one protein chosen from PBP2a and PBP2b in said bacterial strain.

[0090] The antibiotic used is a beta-lactam antibiotic, meaning it contains a beta-lactam nucleus. This antibiotic is chosen from cefoxitin and 6-A-P-A (6-aminopenicillanic acid).

[0091] Cefoxitin, CAS number 35607-66-0, is a beta-lactam antibiotic, classified as a second-generation cephalosporin. Cefoxitin exerts a bactericidal action by inhibiting cell wall synthesis.

[0092] 6-Aminopenicillanic acid, abbreviated 6-APA, CAS number 551-16-6, is a penicillin derivative. Preferably, the antibiotic used for induction step (a) is cefoxitin.

[0093] Induction of PBP2a or PBP2c expression is achieved by incubating the biological sample in the presence of a suitable amount of antibiotic, typically at a temperature between 30° and 40° Celsius. Incubation of the biological sample will preferably take place at 37° C, with shaking.

[0094] According to a particular implementation of the method of the invention, the incubation step (a) is carried out for a duration of at least 15 minutes.

[0095] Preferably, this incubation step (a) is carried out for a period of less than 3 hours, or less than 2 hours, or preferably less than 1 hour.

[0096] Advantageously, the incubation time may be at least 15 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 35 minutes, at least 40 minutes or at least 45 minutes.

[0097] In particular, this incubation step (a) is carried out for one of the following durations:

[0098] From 15 to 180 minutes;

[0099] From 15 to 120 minutes;

[0100] From 15 to 90 minutes; or

[0101] From 15 to 60 minutes.

[0102] As presented in the examples, in the absence of this step of inducing the expression of PBP2a or PBP2c, certain strains of methicillin-resistant S. aureus are not identified as such, because the detection of one of the PBP2a or PBP2c proteins is impossible due to the too low expression of said protein in said strains.

[0103] Step (b) of isolation of bacteria

[0104] Bacteria may be isolated by any means known to those skilled in the art, in particular by centrifugation.

[0105] According to one implementation of the method, step (b) also comprises a step of selective lysis of the non-bacterial cells present in the biological sample, this selective lysis step being carried out before centrifugation of the sample.

[0106] Detergent compounds allow lysis of animal cells by dissociation of the membrane. Since bacteria are composed of a rigid peptidoglycan wall, they are not lysed by the action of detergent.

[0107] A detergent compound may for example be selected from the following group of compounds: saponin, Triton X100 or Sodium Dodecyl Sulfate (SDS). In particular, when the biological sample is a blood sample, step (b) of isolating the bacteria is advantageously carried out concomitantly with lysis of the blood cells present in the sample, by adding a detergent compound.

[0108] Step (c) of lysis of bacteria and hydrolysis of bacterial proteins

[0109] Different methods of bacterial cell lysis can be used. Examples include thermal methods (temperature above 100°C for 10 minutes, or freezing in liquid nitrogen), enzymatic methods (action of lysozyme or lyticase) or mechanical methods (high pressure, grinding or sonication).

[0110] According to a preferred implementation of the method of the invention, the lysis of the bacteria is carried out by sonication.

[0111] The hydrolysis of bacterial proteins into peptides is generally carried out by one of two processes: a) By the action of chemical agents such as hydroxyl radicals which induce random cleavages at the level of peptide bonds, or b) By the action of proteolytic enzymes (proteases) which have a hydrolysis action on protein bonds.

[0112] According to a preferred implementation of the method, the hydrolysis of the bacterial proteins in step (c) is an enzymatic hydrolysis.

[0113] Commonly used proteases include pepsin, which hydrolyzes peptide bonds preferentially before aromatic amino acids (tyrosine, tryptophan, and phenylalanine), endoproteinase GluC, which cleaves peptide bonds at glutamate residues, and trypsin, which cleaves proteins at the C-terminal side of lysine and arginine amino acids.

[0114] According to a preferred implementation of the method of the invention, trypsin is used as an enzyme for the step of hydrolysis of bacterial proteins. Trypsin is in fact preferred for the specific nature of its activity, the adapted size of the peptides that it generates, and the nature of the “tryptic” peptides which have on the C-terminal side an amino acid which can be positively charged (lysine or arginine), thus facilitating analysis by mass spectrometry (analysis of charged molecules).

[0115] A specific protocol for step (c) is presented in the experimental section.

[0116] Step (d) of analysis by targeted mass spectrometry

[0117] Mass spectrometry is a physical analysis technology used to detect and identify molecules of interest. It is also known as single reaction monitoring, multiple reaction monitoring, or parallel reaction monitoring. Its principle lies in the gas-phase separation of charged molecules (ions) based on their mass-to-charge ratio (m / z).

[0118] Mass spectrometers comprise: i) an ionization source intended to ionize the molecules to be analyzed, i.e. to confer a positive or negative charge to these molecules; ii) a mass analyzer intended to separate the ionized molecules according to their mass to charge ratio (m / z); iii) a detector intended to measure the signal produced either directly by the molecular ions or by ions produced from the molecular ions, as detailed below.

[0119] The ionization step required for mass spectrometry can be implemented by any method known to those skilled in the art. The ionization source allows the molecules to be measured to be in a gaseous and ionized state. An ionization source can be used either in positive mode to study positive ions, or in negative mode to study negative ions. Several types of sources exist and will be used depending on the desired result and the molecules analyzed.

[0120] The mass analyzer in which the step of separating the ionized markers according to their mass / charge ratio (m / z) is implemented is any mass analyzer known to those skilled in the art. Mention may be made of low-resolution analyzers, of the quadrupole or quadrupole (Q), 3D ion trap (IT) or linear (LIT) type, also called ion trap, and high-resolution analyzers, allowing the exact mass of the analytes to be measured and which use in particular the magnetic sector coupled to an electrical sector, the time of flight (TOF), the orbitrap.

[0121] The separation of molecular ions based on their m / z ratio can be performed once (single mass spectrometry or MS), or several successive MS separations can be carried out. When two successive MS separations are performed, the analysis is called MS / MS or MS2. When three successive MS separations are performed, the analysis is called MS / MS / MS or MS3.

[0122] Targeted mass spectrometry is a variant in which the molecules of interest sought by this analysis technique are previously known, and the analysis is used to identify their presence or absence in a sample.

[0123] Targeted approaches (Multiple Reaction Monitoring, MRM; Parallel Reaction Monitoring, PRM; Multiple Reaction Monitoring-High Resolution, MRM-HR; Multiple Reaction Monitoring cubed, MRM3, DIA / SWATH) consist of the selection by a first analyzer of a precise mass corresponding to the peptide of interest which is then fragmented in a collision cell. The generated fragments are then monitored by a third analyzer and their signal / intensity is measured.

[0124] In the case of chromatographic couplings, the signal of the fragments is measured as a function of time to be represented in the form of a chromatogram, the appearance of concomitant chromatographic peaks (simultaneous detection of the fragments) therefore being evidence of the presence of the peptide in the sample.

[0125] These approaches require prior work of selection and validation of marker peptides to ensure their sequence / mass uniqueness (or mass / charge ratio, m / z) and their detectability.

[0126] The principle of SRM mode, or MRM mode, is to specifically select a precursor ion, fragment it, and then specifically select one of its fragment ions. For such applications, triple quadrupole devices or triple quadrupole hybrids with ion traps are generally used.

[0127] The DIÀ / SWÀTH analysis mode consists of recording fragmentation spectra of contiguous selection windows of precursor ions, most often overlapping by 1 mass-to-charge ratio (m / z) unit, the windows being characterized by a fixed or variable width in m / z, or by using a sliding window of fixed width in m / z, while ensuring that the total cycle time to cover all of these windows allows each chromatographic peak to be sampled by at least 5 points.

[0128] According to a preferred implementation of the invention, the mass spectrometry analysis is targeted during the analysis (SRM / MRM, MRM, MRM3, PRM type mode) or after the analysis (DIA / SWÀTH type mode).

[0129] More preferably, the targeted mass spectrometry analysis is carried out in MRM or MRM3 mode, and most preferably is carried out in MRM3 mode.

[0130] Targeted mass spectrometry is coupled with peptide separation, preferably by chromatographic or electrophoretic separation of the peptides.

[0131] The separation of the peptides can be carried out by any technique known to those skilled in the art, and in particular can be carried out by reverse phase liquid chromatography, by normal phase liquid chromatography, by hydrophilic phase liquid chromatography, or by capillary electrophoresis.

[0132] Preferably, the separation of the peptides is carried out by reverse-phase liquid chromatography. The peptides sought during this analysis step are peptides derived from the PBP2a or PBP2c proteins, specific to said proteins.

[0133] It is understood that at least one peptide from these proteins can be detected, but that preferably several peptides will be detected during the analysis, which supports the results obtained.

[0134] According to a preferred implementation of the method of the invention, the at least one peptide derived from the PBP2a or PBP2c protein which is detected, that is to say the presence of which is demonstrated by targeted mass spectrometry, is chosen from the group of 12 peptides having the following sequences: SEQ ID NO. 3 to SEQ ID NO. 14 presented in Tables 1 and 2 below.

[0135] Table 1. Sequences of peptides from PBP2a

[0136] Table 2. Sequences of peptides from PBP2c Advantageously, all these peptides were selected in conserved areas of the proteins and are therefore also identified in the variant proteins of PBP2a and PBP2c. The method according to the invention can be carried out on any type of biological sample likely to contain a strain of Staphylococcus aureus.

[0137] According to a particular implementation of the method, the biological sample is chosen from:

[0138] - A biological fluid, for example blood, serum, plasma, urine, cerebrospinal fluid, and tears;

[0139] - A bacterial culture, for example a blood culture, a bacterial colony on agar, a bacterial culture broth;

[0140] - A food sample, and

[0141] - any other type of biological sample.

[0142] This will preferably be a biological fluid, in particular a blood sample (blood, serum, plasma), and more particularly the medium of a positive blood culture containing Staphylococcus aureus.

[0143] The term "blood culture" means a blood sample taken from a patient and then incubated under suitable conditions to allow proliferation of any bacteria present in the sample.

[0144] This blood culture can be carried out in blood culture bottles such as those sold in the Bact / Àlert range distributed by BioMérieux, or those in the Bactec range distributed by Becton Dickinson.

[0145] Kit for implementing the process

[0146] The present invention also relates to a kit for implementing the method as described above, comprising:

[0147] - an antibiotic of the beta-lactam class chosen from the following group: cefoxitin and 6-ÀPÀ (6-aminopenicillanic acid),

[0148] - trypsin,

[0149] - a reagent allowing selective lysis of non-bacterial cells present in the biological sample, for example a detergent.

[0150] For example, among the reagents allowing selective lysis of non-bacterial cells, we will cite a detergent compound selected from the following group of compounds: saponin, Triton X100 or Sodium Dodecyl Sulfate (SDS).

[0151] EXAMPLES

[0152] The examples presented below are intended to illustrate the method according to the invention, but are in no way a limitation of the subject of the invention.

[0153] In particular, in the examples presented below, the antibiotic used during the induction step is cefoxitin, but it is understood that 6-ÀPÀ may also be used. Example 1. Materials and Methods

[0154] Induction step (a) is carried out according to the following protocol:

[0155] Perform asepsis of the blood culture bottle septum

[0156] - Using a 21 G syringe and needle, collect 3.8 mL of positive blood culture medium and transfer it to a 15 mL tube.

[0157] - Add 200 pL of a 8 pg / mL cefoxitin solution

[0158] Homogenize the mixture then incubate the tube at 37°C with shaking (180 rpm) for 30 minutes

[0159] Step (b) of isolating the bacteria is advantageously carried out concomitantly with lysis of the blood cells, according to the following protocol:

[0160] - After the 30 minutes of induction, transfer 1 mL of medium into a 1.5 mL tube and add 200 µl of a 12% SDS solution then vortex for 10 seconds. Centrifuge for 2 minutes at 16100 g and discard the supernatant. Resuspend the pellet in 1 mL of physiological saline.

[0161] Centrifuge for 1 minute at 16100 g and discard the supernatant. Resuspend in 1 mL of physiological saline.

[0162] Step (c) of mechanical lysis of bacteria and enzymatic digestion of proteins is carried out according to the following protocol:

[0163] - Transfer 200 pL of the bacterial suspension prepared previously into a 1.5 mL Eppendorf LoBind tube containing approximately 70 mg of glass beads (Glass beads, acid-washed, 150-212 pm, Sigma-Aldrich, ref G1145)

[0164] - Add 50 pL of a 1 mg / mL trypsin solution prepared extemporaneously in 150 mM ammonium bicarbonate buffer from lyophilized trypsin. Immediately place the sample in the water bath of a sonicator set to 50°C then start 10 ultrasound cycles (low power) o 30 seconds ultrasound on o 30 seconds ultrasound off

[0165] Directly at the end of the 10 ultrasound cycles, add 5 pL of formic acid. Centrifuge the tube at 9600 g for 5 minutes.

[0166] - Transfer 150 pL of supernatant into a 2 mL amber glass vial fitted with an insert for mass spectrometry analysis.

[0167] Step (d) of analysis by targeted mass spectrometry is carried out according to the following protocol:

[0168] A 5 pL volume of sample from the previous lysis / digestion step is injected onto the chromatographic system. The analysis is performed on a Waters XBridge Peptide BEH C18 reversed-phase column, 1 mm internal diameter, 100 mm length, 3.5 pm particle size, 130 Å pore size using a chromatographic system equipped with an Agilent 1290 infinity LC pump, an Agilent 1290 Autosampler, and an Agilent 1290 TCC column oven set at 60 °C. The gradient used for the chromatographic separation is shown in Table 3. Solvent A: H2O + 0.1% formic acid

[0169] Solvent B: Acetonitrile + 0.1% formic acid

[0170] Table 3. Analysis parameters

[0171] The output of the chromatographic system is directly connected to the ionization source of a QTRAP 6500+ mass spectrometer (Sciex) for online analysis of peptides resulting from the digestion of bacterial proteins. The mass spectrometer is operated in MRM or MRM-cubed (MRM3) mode and the transitions monitored, for the PBP2a protein, are detailed in Table 4.

[0172] Table 4. List of transitions followed for the detection of PBP2a.

[0173] The transitions monitored for the PBP2c protein are detailed in Table 5.

[0174] Table 5. List of transitions monitored for PBP2c detection

[0175] The mass spectrometer parameters for MRM mode analysis are detailed in Table 6 below.

[0176] Table 6. Mass spectrometer parameters for MRM mode analysis

[0177] The mass spectrometer parameters for MRM3 mode analysis are detailed in Table 7 (peptide VÀLELGSK) and Table 8 (peptide FQITTSPGSTQK) below.

[0178] Table 7. Mass spectrometer parameters for analysis in MRM3 mode Table 8. Mass spectrometer parameters for analysis in MRM3 mode

[0179] Example 2. First results

[0180] Figures 1 and 2 illustrate the necessity of the induction step for the detection of peptides from PBP2a by MRM.

[0181] Chromatograms A are from the analysis of strains without an induction step, chromatograms B correspond to the analysis of the same strains after an induction step.

[0182] In the absence of induction, the peaks of peptides from PBP2a are confused with the background noise and therefore undetectable.

[0183] On the contrary, after an induction step, the characteristic peaks are observed: they are correctly drawn and above the background noise. PBP2a is correctly detected.

[0184] Blood cultures were inoculated for 98 strains of MRSA and 19 strains of methicillin-susceptible Staphylococcus aureus (MSSA) not expressing PBP2a, then samples were prepared to bottle positivity and analyzed according to the protocols in Example 1.

[0185] The area under the curve was measured for each transition. Although not expressing PBP2a, the area under the curve was also measured for samples of MSSA-sensitive strains on the peptide elution window, in order to obtain a baseline value. Indeed, the signal of a transition can be polluted by noise or interference due to the matrix, it is therefore necessary to evaluate this baseline in a matrix not containing the analyte (here PBP2a) in order to establish thresholds above which we can confirm the presence of the peptides.

[0186] For each transition, the threshold corresponds to 150% of the maximum area measured on the peptide elution window for the MSSA control samples.

[0187] Example 3. MRM spectrometry results

[0188] All MRM transitions for which the area value is greater than the threshold value were considered positive and are scored as 1 in the following results tables. Transitions for which the area is less than the threshold value are scored as 0 and therefore considered negative. A sample was considered identified as comprising an MRSA strain in cases where at least 3 peptides are detected with at least 2 positive transitions.

[0189] Tables 9 and 10 below correspond to the results obtained during the MRM analysis of the 98 MRSA without the induction step. Tables 11 and 12 below correspond to the results obtained during the MRM analysis of the 98 MRSA with the induction step.

[0190] Table 9: Validation table of MRM transitions of PBP2a from MRSAIb to MRSA49b strains prepared WITHOUT induction step

[0191]

[0192] Table 10. Validation table of PBP2a MRM transitions of strains

[0193] MRSA50b to MRSA98b prepared WITHOUT induction step

[0194]

[0195]

[0196] Table 11. Validation table of PBP2a MRM transitions from MRSAIb to MRSA49b strains prepared WITH induction step

[0197]

[0198] Table 12. Validation table of PBP2a MRM transitions from MRSA50b to MRSA98b strains prepared WITH induction step

[0199] Based on the results presented in Tables 9 to 12, the following conclusions can be drawn:

[0200] Without induction step, 38 out of 98 MRSAs have at least 2 positive transitions for at least 3 peptides, which corresponds to a detection sensitivity of 39%. With the induction step, 96 out of 98 MRSAs have at least 2 positive transitions for at least 3 peptides. This corresponds to a 98% sensitivity of MRSA detection with these validation criteria. Only the MRSA9b and MRSA41b strains are not correctly identified because only 2 peptides are detected with 2 transitions for the MRSA41b strain and 1 peptide with 2 transitions for the MRSA9b strain.

[0201] All MSSA analyzed using the same method have, for each transition, an area under the curve value lower than the threshold values ​​set previously. This means that no MSSA is identified as MRSA, which is equivalent to a specificity of 100%.

[0202] Example 4. MRM3 spectrometry results for PBP2A

[0203] MRM3 transitions for which the area value was greater than the threshold value were considered positive and are scored 1. Transitions for which the area was less than or equal to the threshold value were scored 0 and considered negative. A sample was considered identified as MRSÀ if at least 1 MRM3 transition was detected positive. The 19 MSSÀ strains were analyzed using the same method and the results are presented in the following tables.

[0204] Table 13 corresponds to the results obtained during the MRM3 analysis of the 98 MRSÀ without the induction step. It represents the validations of the MRM3 transitions of the 98 MRSÀ prepared WITHOUT the induction step

[0205] Table 14 corresponds to the results obtained during the MRM3 analysis of the 98 MRSAs with the induction step. It represents the validations of the MRM3 transitions of the 98 MRSAs prepared with the induction step.

[0206] Table 13. Results of MRM3 analysis without induction step

[0207] Table 14. MRM3 analysis results with induction step

[0208] Nineteen methicillin-sensitive strains (MSSÀI b, 2b, 3b, 4b, 5b, 6b, 7b, 8b, 9b, 10b, 11b, 12b, 13b 14b, 15b, 16b, 17b, 18b and 19b) were tested: no peptides from PBP2a were detected, as expected. Results with all a value of zero are not presented in detail.

[0209] Without the induction step, 87 out of 98 strains showed at least one positive transition, which corresponds to 89% sensitivity (Table 12).

[0210] With the induction step, all MRSA strains tested have at least one positive MRM3 transition, which corresponds to 100% sensitivity (Table 13). All MSSA analyzed using the same method (with the induction step) have, for each transition, an area under the curve value less than or equal to the threshold values ​​set previously. This means that no sensitive MSSA strain is identified as MRSÀ, which is equivalent to a specificity of 100%.

[0211] Conclusions

[0212] The performance of the process according to the invention is presented in Table 15 below, which illustrates the importance of the induction step.

[0213] Table 15. Sensitivity of the method of the invention

[0214] These results show that the method according to the invention allows rapid identification of MRSÀ in less than 1.5 hours, directly from a positive blood sample (blood culture), and with superior performance to other methods currently on the market (98% sensitivity and 100% specificity in MRM, and 100% sensitivity and 100% specificity in MRM3).

[0215] Implementation of the sample preparation protocol is simple and the cost in consumables per analysis is minimal.

[0216] Furthermore, the possibility of non-detection, in the case of a PBP2a variant protein with one or more point mutations, is very unlikely, given that the analysis is based on the detection of 8 different peptides of the PBP2a protein.

[0217] Finally, it was also shown that the induction step of the method is necessary for the detection of the PBP2c protein in a Staphylococcus aureus strain expressing the protein. The results presented in Figure 7 show that detection would have been impossible without the prior induction step by incubation with a beta-lactam antibiotic. REFERENCES

[0218] WO 2011 / 045544

[0219] Kirby, W. M. M. (1944). Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 99, 452-453.

[0220] Felten, A., Grandry, B., Lagrange, PH, and Casin, I. (2002). Evaluation of Three Techniques for Detection of Low-Level Methicillin-Resistant Staphylococcus aureus (MRSA): a Disk Diffusion Method with Cefoxitin and Moxalactam, the Vitek 2 System, and the MRSA-Screen Latex Agglutination Test. J Clin Microbiol 40, 2766-2771.

[0221] Sparbier K, Lange C, Jung J, Wieser A, Schubert S, Kostrzewa M. MALDI biotyper-based rapid resistance detection by stable-isotope labeling. J Clin Microbiol. 2013 Nov;51 (11 ):3741 -8.

[0222] Tenover, F.C., Jones, R.N., Swenson, J.M., Zimmer, B., McAllister, S., and Jorgensen, J.H. (1999). Methods for Improved Detection of Oxacillin Resistance in Coagulase- Negative Staphylococci: Results of a Multicenter Study. J Clin Microbiol 37, 4051 -4058.

[0223] Dupieux, C., Bouchiat, C., Larsen, A.R., Pichon, B., Holmes, M., Teale, C., Edwards, G., Hill, R., Decousser, J.-W., Trouillet-Assant, S., et al. (2017). Detection of mecC-Positive Staphylococcus aureus: What To Expect from Immunological Tests Targeting PBP2a? J Clin Microbiol 55, 1961 -1963.

[0224] Charretier, Y., Dauwalder, O., Franceschi, C., Degout-Charmette, E., Zambardi, G., Cecchini, T., Bardet, C., Lacoux, X., Dufour, P., Veron, L., et al. (2015). Rapid Bacterial Identification, Resistance, Virulence and Type Profiling using Selected Reaction Monitoring Mass Spectrometry. Sci Rep 5, 13944.

[0225] Neil JR, Verma A, Kronewitter SR, McGee WM, Mullen C, Viirtola M, Kotovuori A, Friedrich H, Finell J, Rannisto J, Syka J EP, Stephenson JL Jr. Rapid MRSA detection via tandem mass spectrometry of the intact 80 kDa PBP2a resistance protein. Sci Rep. 2021 Sep 15;11 (1 ):18309.

Claims

DEMANDS 1. A method for determining the methicillin resistance properties of a strain of Staphylococcus aureus present in a biological sample, comprising the following steps: a) incubating the biological sample containing said strain of Staphylococcus aureus for at least 15 minutes in the presence of a beta-lactam antibiotic selected from cefoxitin and 6-APA (6-aminopenicillanic acid), b) isolating the bacteria present in said biological sample, c) lysing the bacteria and hydrolyzing the bacterial proteins to obtain a peptide mixture, d) analyzing this peptide mixture by targeted mass spectrometry coupled with peptide separation, detecting at least one peptide derived from the PBP2a protein (SEQ ID NO. 1) or the PBP2c protein (SEQ ID NO. 2).2) during the analysis step (d) being indicative of the methicillin resistance of the strain of Staphylococcus aureus present in said biological sample.

2. A method according to claim 1, characterized in that the separation of peptides is a separation by chromatography or by electrophoresis.

3. Method according to claim 1 or 2, characterized in that the mass spectrometry analysis is targeted during the analysis (SRM / MRM, MRM3, PRM type mode) or after the analysis (DIA / SWATH type mode).

4. A method according to any one of claims 1 to 3, characterized in that the incubation step (a) is carried out for a period of between 15 and 180 minutes.

5. A method according to any one of claims 1 to 4, characterized in that step (b) also includes a step of selective lysis of non-bacterial cells present in the biological sample.

6. A process according to any one of claims 1 to 5, characterized in that the hydrolysis of bacterial proteins in step (c) is an enzymatic hydrolysis.

7. A method according to claim 6, characterized in that the enzyme is trypsin.

8. A method according to any one of claims 1 to 7, characterized in that the at least one detected peptide is chosen from the group of 12 peptides having the following sequences: SEQ ID NO. 3 to SEQ ID NO.

14.

9. A method according to any one of claims 1 to 8, characterized in that the biological sample is chosen from: - A biological fluid such as blood, serum, plasma, urine, cerebrospinal fluid, and 37 tears ; - A bacterial culture such as a blood culture, a colony on agar, or a culture broth; - A food sample, and - any other type of biological sample.

10. Kit for implementing the process according to any one of claims 1 to 9, comprising: - at least one antibiotic from the beta-lactam class chosen from cefoxitin and 6-APA (6-aminopenicillanic acid), - trypsin, and - a reagent allowing selective lysis of non-bacterial cells present in the biological sample, for example a detergent. 38